Gene Therapy for Spinal Muscular Atrophy (SMA): Spinraza and Beyond
Disease Mechanism
SMA is caused by homozygous loss-of-function mutations in SMN1, leading to deficiency of survival motor neuron (SMN) protein and progressive motor neuron degeneration.
Spinraza (Nusinersen)
- Mechanism: Antisense oligonucleotide that modifies SMN2 splicing to increase functional SMN protein.
- Administration: Intrathecal injection (loading doses at days 0, 14, 28, 63; then every 4 months).
- Efficacy: Clinical trials show improved motor milestones, survival, and quality of life across SMA types.
- Safety: Generally well-tolerated; common adverse events include headache, back pain, post-lumbar puncture syndrome.
- Cost: Over $750,000 first year; patient assistance programs exist.
Emerging Therapies
- Onasemnogene abeparvovec (Zolgensma): AAV9-mediated SMN1 gene replacement via one-time IV infusion.
- Risdiplam (Evrysdi): Oral small-molecule SMN2 splicing modifier.
- Future: Next-generation gene editing, neuroprotective agents, and combination regimens.
Early diagnosis through newborn screening and prompt treatment initiation maximize benefit. Multidisciplinary SMA clinics optimize care coordination.
Genetic Disorders - Related Articles
- Elevated Microsomal Antibodies (MAB): Causes and Clinical Significance
- Understanding the Connection Between BPD and Childlike Behaviors
- Birth Defects in Animals: Causes, Outcomes, and Veterinary Care Options
- Understanding Proliferative Retinopathy: Causes, Complications & Treatment
- Empty Nest Syndrome: Emotional Impact, Coping Strategies, and Growth Opportunities
- Diagnosing Mononucleosis: Clinical Evaluation, Monospot Test, CBC, and EBV-Specific Antibody Testing
- Disease Prevention: Impact on Development, Economic Growth, and Health Equity
